Nextgen Biomed Ltd
Tel Aviv Stock Exchange NXGN.TA
Nextgen Biomed Ltd Price to Sales Ratio (P/S) on January 14, 2025
Nextgen Biomed Ltd Price to Sales Ratio (P/S) is NA on January 14, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
-
Nextgen Biomed Ltd 52-week high Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
-
Nextgen Biomed Ltd 52-week low Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
-
Nextgen Biomed Ltd average Price to Sales Ratio (P/S) for the last 52 weeks is NA.
Key data
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
Market news
Loading...
Tel Aviv Stock Exchange: NXGN.TA
| CEO | Mr. Harel Hershtik |
| IPO Date | Aug. 12, 2002 |
| Location | Israel |
| Headquarters | 132 Azrieli Towers Round Building |
| Employees | 5 |
| Sector | Health Care |
| Industries | |
Description
Nextgen Biomed Ltd develops topical treatment for psoriasis. The company was formerly known as Sela Group.Com Ltd. and changed its name to Nextgen Biomed Ltd in February 2010. Nextgen Biomed Ltd was incorporated in 1990 and is based in Tel Aviv, Israel.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email